C
앱토크롬
109960KOSDAQ기타 전문 도매업51.5 / 100
Reference Date: 2026-04-13
Financial Score22.0 / 40
News Sentiment12.5 / 25
Momentum7.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Rose 9.3% over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
AppTalkrom primarily engages in pharmaceutical distribution, including topical and digestive medications, and real estate leasing. Its subsidiary, Aprogen Inc., specializes in nuclear power plant insulation systems. In 2024, the company achieved pharmaceutical sales of 7,380 million won, insulation business revenue of 8,459 million won, and total sales of 16,400 million won.
Number of Employees
16people
Average Salary
53.3M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 15.634.0Point
PBR
0.13Industry Average 0.637.0Point
Half of industry avg (excellent)
ROE
-1.85Industry Average 2.090.0Point
Well below industry avg
Debt Ratio
0.71Industry Average 7.878.0Point
Half of industry avg (excellent)
Trend 2023~20253.0 / 10 points
Revenue Growth Rate
0.0 / 3
Avg ▼18.9% (2-year basis)
Operating Profit Growth Rate
3.0 / 3
Avg ▲38.0% (2-year basis)
ROE Trend
0.0 / 4
Avg ROE -3.2% (declining, 3yr)
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position1.0Point
Near 52w low (7%, downtrend)
Current 176Won52-week high 50652-week low 150
1-month return5.0Point
1m +9.32% (rising)
Volume trend1.0Point
Volume decreasing
Detailed Disclosure
7 totalPositive 0Neutral 7Negative 0
- Neutral[기재정정]주권관련사채권의취득결정 (제27회차)2026-04-10
- Neutral[기재정정]주요사항보고서(주권관련사채권양도결정)2026-03-31
- Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-03-31
- Neutral[기재정정]투자판단관련주요경영사항 ((주)에이프로젠의 AP096, Adalimumab Biosimilar 개발을 위한 투자금 분담 계약 체결)2026-03-31
- Neutral정기주주총회결과2026-03-30